334 related articles for article (PubMed ID: 35001170)
21. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies.
Geoffroy MC; Jaffray EG; Walker KJ; Hay RT
Mol Biol Cell; 2010 Dec; 21(23):4227-39. PubMed ID: 20943951
[TBL] [Abstract][Full Text] [Related]
22. The SUMO protease SENP6 is a direct regulator of PML nuclear bodies.
Hattersley N; Shen L; Jaffray EG; Hay RT
Mol Biol Cell; 2011 Jan; 22(1):78-90. PubMed ID: 21148299
[TBL] [Abstract][Full Text] [Related]
23. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.
Van Damme E; Laukens K; Dang TH; Van Ostade X
Int J Biol Sci; 2010 Jan; 6(1):51-67. PubMed ID: 20087442
[TBL] [Abstract][Full Text] [Related]
24. The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation.
Schilling EM; Scherer M; Reuter N; Schweininger J; Muller YA; Stamminger T
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903803
[TBL] [Abstract][Full Text] [Related]
25. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.
Han Y; Huang C; Sun X; Xiang B; Wang M; Yeh ET; Chen Y; Li H; Shi G; Cang H; Sun Y; Wang J; Wang W; Gao F; Yi J
J Biol Chem; 2010 Apr; 285(17):12906-15. PubMed ID: 20181954
[TBL] [Abstract][Full Text] [Related]
26. Viral DNA Binding Protein SUMOylation Promotes PML Nuclear Body Localization Next to Viral Replication Centers.
Stubbe M; Mai J; Paulus C; Stubbe HC; Berscheminski J; Karimi M; Hofmann S; Weber E; Hadian K; Hay R; Groitl P; Nevels M; Dobner T; Schreiner S
mBio; 2020 Mar; 11(2):. PubMed ID: 32184235
[TBL] [Abstract][Full Text] [Related]
27. Promyelocytic leukemia nuclear body-like structures can assemble in mouse oocytes.
Udagawa O; Kato-Udagawa A; Hirano S
Biol Open; 2022 Jun; 11(6):. PubMed ID: 35579421
[TBL] [Abstract][Full Text] [Related]
28. RING tetramerization is required for nuclear body biogenesis and PML sumoylation.
Wang P; Benhenda S; Wu H; Lallemand-Breitenbach V; Zhen T; Jollivet F; Peres L; Li Y; Chen SJ; Chen Z; de Thé H; Meng G
Nat Commun; 2018 Mar; 9(1):1277. PubMed ID: 29599493
[TBL] [Abstract][Full Text] [Related]
29. Unravelling the molecular interplay: SUMOylation, PML nuclear bodies and vascular cell activity in health and disease.
Berkholz J; Karle W
Cell Signal; 2024 Jul; 119():111156. PubMed ID: 38574938
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
Bailey D; O'Hare P
Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
[TBL] [Abstract][Full Text] [Related]
31. A Tale of Usurpation and Subversion: SUMO-Dependent Integrity of Promyelocytic Leukemia Nuclear Bodies at the Crossroad of Infection and Immunity.
Patra U; Müller S
Front Cell Dev Biol; 2021; 9():696234. PubMed ID: 34513832
[TBL] [Abstract][Full Text] [Related]
32. The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.
Reuter N; Schilling EM; Scherer M; Müller R; Stamminger T
J Virol; 2017 May; 91(10):. PubMed ID: 28250117
[TBL] [Abstract][Full Text] [Related]
33. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
34. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
35. TGF-β induces PML SUMOylation, degradation and PML nuclear body disruption.
El-Asmi F; El-Mchichi B; Maroui MA; Dianoux L; Chelbi-Alix MK
Cytokine; 2019 Aug; 120():264-272. PubMed ID: 31153006
[TBL] [Abstract][Full Text] [Related]
36. Stability of Smyd1 in endothelial cells is controlled by PML-dependent SUMOylation upon cytokine stimulation.
Becker S; Steinemann G; Karle W; Roos K; Liem CH; Muralikumar S; Volkamer A; Munz B; Zakrzewicz A; Berkholz J
Biochem J; 2021 Jan; 478(1):217-234. PubMed ID: 33241844
[TBL] [Abstract][Full Text] [Related]
37. Effects of arsenic on modification of promyelocytic leukemia (PML): PML responds to low levels of arsenite.
Hirano S; Watanabe T; Kobayashi Y
Toxicol Appl Pharmacol; 2013 Dec; 273(3):590-9. PubMed ID: 24135626
[TBL] [Abstract][Full Text] [Related]
38. Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation.
Saito Â; Souza EE; Costa FC; Meirelles GV; Gonçalves KA; Santos MT; Bressan GC; McComb ME; Costello CE; Whelan SA; Kobarg J
J Proteome Res; 2017 Sep; 16(9):3147-3157. PubMed ID: 28695742
[TBL] [Abstract][Full Text] [Related]
39. Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation.
Maroui MA; Maarifi G; McManus FP; Lamoliatte F; Thibault P; Chelbi-Alix MK
Mol Cell Proteomics; 2018 Jun; 17(6):1196-1208. PubMed ID: 29535160
[TBL] [Abstract][Full Text] [Related]
40. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
